



**November 07 , 2025**

**Ref:- GHL/2025-26/EXCH/77**

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code: 543654**

**Symbol: MEDANTA**

**Sub: Investor Presentation**

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the Second Quarter and Half Year ended September 30, 2025 Results.

Kindly take the above on record.

Thanking you,


Yours faithfully

**For Global Health Limited**

RAHUL Digitally signed  
by RAHUL  
RANJAN  
Date:  
2025.11.07  
17:52:25 +05'30'

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**





# GLOBAL HEALTH LIMITED

Dedicated to Life

**Investor Presentation**

**Q2 and H1 FY2026**

**7<sup>th</sup> November, 2025**



- This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.
- These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.

# Contents

- 01 Q2 and H1 FY2026 Performance Update
- 02 Project Update and Capex Plan
- 03 Medanta's Journey, Purpose and Model of Healthcare
- 04 Annexures

01

# **Q2 and H1 FY2026 Performance Update**

# Q2 FY2026 performance summary

Revenue Growth of 15% y-o-y and EBITDA growth (ex Noida) of 14% y-o-y

Total Income<sup>1</sup>

INR 11,189 million

Q2 FY25  
9,748 million

▲  
14.8%

EBITDA<sup>3</sup>  
ex Noida<sup>2</sup>

INR 2,804 million

Margin: 25.2%

Q2 FY25  
2,465 million  
Margin: 25.3%

▲  
13.7%

EBITDA<sup>3</sup>  
incl. Noida

INR 2,607 million

Margin: 23.3%

Q2 FY25  
2,465 million  
Margin: 25.3%

▲  
5.7%

PAT

INR 1,584 million

Margin: 14.2%

Q2 FY25  
1,308 million  
Margin: 13.4%

▲  
21.1%

Occupied Bed  
Days

155,729

Q2 FY25  
144,564

▲  
7.7%

ARPOB\* (INR)

65,570

Q2 FY25  
62,141

▲  
5.5%

ALOS (days)

3.06

Q2 FY25  
3.20

▼  
-4.5%

Patient Footfalls

50,925  
In-patients

890,750  
Out-patients

▲  
12.7%  
Q2 FY25  
45,169

▲  
14.9%  
Q2 FY25  
775,395

1. Noida generated Total Income of INR 39 million in Q2 FY26
2. Noida facility resulted in EBITDA loss of INR 197 million during the quarter
3. EBITDA represents EBITDA before ESOP expenses

\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

\*\* Outpatients volume reflects OPD encounters

# Q2 FY2026 performance summary

## Revenue growth of 15% y-o-y, primarily led by increase in patient volumes and realization

- Consolidated Total Income of INR 11,189 million, compared to INR 9,748 million in Q2 FY25; reflecting a growth of 14.8 % y-o-y
- EBITDA<sup>1</sup> (ex-Noida<sup>3</sup>) grew 13.7 % y-o-y to INR 2,804 with margins of 25.2% compared to 25.3% in Q2 FY25. Including Noida, EBITDA was INR 2,607 million, up 5.7% y-o-y, with margins at 23.3%
- Medanta Noida commenced operations in September 2025. The hospital generated Revenue of INR 39 million and EBITDA loss of INR 197 million
- Profit After Tax was INR 1,584 million, growth of 21.1% y-o-y. PAT margins improved to 14.2% from 13.4% in Q2 FY25
- During the quarter, 37 new beds were added at Patna, taking total bed addition to 57 beds in H1 FY26 in Patna
- Occupied bed days increased by 7.7% y-o-y, representing an occupancy of ~64% on increased bed capacity
- ARPOB grew by 5.5% y-o-y to INR 65,570 in Q2 FY26, driven by increase in realization and change in speciality mix
- Volume growth remained robust, In-patient count increased by 12.7% and Out-patient count increased by 14.9% y-o-y
- Matured hospitals revenue was INR 7,200 million, growth of 5.4% y-o-y. EBITDA was INR 1,696 million, growth of 0.4% y-o-y
- Developing hospitals ex Noida, Revenue was INR 3,531 million, growth of 28.3% y-o-y. EBITDA increased 34.0% YoY to INR 1,112 million, with margins improving to 31.5% compared to 30.1% in Q2 FY25. Including Noida, EBITDA stood at INR 915 million, up 10.2% y-o-y, with margin of 25.6%, reflecting the impact of initial ramp-up costs
- International Patients Revenue increased by 48.5% y-o-y to INR 762 million in Q2 FY26, driven by increased international patient volume
- OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 23.9% y-o-y to INR 456 million in Q2 FY26

1. EBITDA represents EBITDA before ESOP expenses

2. Noida generated Total Income of INR 39 million in Q2 FY26

3. Noida facility resulted in EBITDA loss of INR 197 million during the quarter



# Medanta Noida: Launched on 1<sup>st</sup> September, 2025

Commenced phase I of 300 beds; 226 beds and 5 OTs operational as at the end of Q2 FY26

## Medanta Noida Overview

**550+**

Planned beds capacity

**226**

Operational beds

**80+**

ICU Beds

**150+**

Experienced  
Doctors

**60+**

Senior clinicians

**500+**


Nurses and  
paramedics

**950+**

Full-time  
employees

**20+**

Super Specialities





# Latest advanced technology deployed at Noida

Providing the latest tools to enable our doctors to deliver the greatest care

**O-arm O2 Surgical Imaging System**



**Da Vinci Xi Robotic System**



**ARTIS icono BiPlane CATH Lab**



**MAGNETOM Lumina 3T MRI**



**SOMATOM Pro. Pulse Dual Source CT**



**ARTIS icono Ceiling with Abbott EP System – CATH Lab**



**Stealth Station S8 Neuro Navigation System**



**Lumenis Pulse 100H Holmium Laser**



**ACUPULSE DUO CO2 Laser System**

**Leica Arveo 8 Digital Visualisation Microscope for Neurosurgery**



# Q2 FY2026 Business Update

## Strengthening the core and building strong pipeline for growth



### Capacity Expansion

- ✓ **Patna:** Total of 37 beds added in Q2 FY26. Total 57 bed addition in H1 FY26
- ✓ **Noida:** Commenced phase 1 of 300 beds in Sep 2025. Operational bed at the end of Q2 FY26 were 226 beds



### Attract Best Talent


- ✓ **49 Doctors on-boarded in** Q2 FY26 across Medanta network hospitals excluding Noida
- ✓ **150+ doctors;** on-boarded in Noida during the quarter
- ✓ **Major on-boarding is across** key clinical departments such as Cardiac, Critical Care and Cancer



### New Medical Equipment Deployed in Q2 FY26 (ex Noida)



**A 128 slice Dual Source CT**  
*Medanta Lucknow*



**MAGNETOM Altea 1.5 Tesla MRI**  
*Medanta Lucknow*




### Continuity of Care

- ✓ **30+** collection centres added in Q2 FY2026, taking collections centre to ~300+
- ✓ **17 operational pharmacy** comprising of, 7 Pharmacies in the Hospital, 2 Mediclinics and 8 Retail Pharmacies


# Key operating metrics: Revenue and profitability

Revenue growth of 14% y-o-y and 6% on a sequential basis and EBITDA up by 14% (ex Noida)


Total Income (INR million)




EBITDA<sup>1</sup> (INR million and margin %)



Profit before tax (INR million and margin%)



Profit after tax (INR million and margin %)




1. EBITDA represents EBITDA before ESOP expenses

\*\*Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers


# Key operating metrics: Volumes, occupancies, ALOS

Occupied bed days grew by 8%, driven by in-patient volume growth of 13% y-o-y, occupancy at 64% in Q2 FY26


## Average census and occupied beds




## ALOS (days)



## IPD volumes ('000)




## OPD volumes ('000)




# Key operating metrics: ARPOB and revenue mix

ARPOB growth driven change in specialty mix; cancer contribution is increasing


ARPOB\* (INR)




IPD Revenue mix by payor category



Domestic and international revenue breakdown



IPD vs OPD revenue breakdown




\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days



# Diverse revenue<sup>1</sup> mix

Significant contribution from complex specialties. Cancer contribution is increasing



- Notes:
- 1. Revenue from healthcare services excludes pharmacy revenue and other income
  - 2. Revenue breakdowns are provided as per internal MIS at the Company's consolidated level
  - 3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery


\*Previous period figures have been regrouped/reclassified to conform to the current period's classification. Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include MHPL

# Growth seen in both mature and new hospitals


## Developing hospitals delivered robust revenue and EBITDA y-o-y growth

### Matured hospitals - Over 6 years


#### Total Income (INR million)




#### EBITDA (INR million and margin %)



#### IPD Volumes (count)




#### ARPOB\* (INR)




### Developing hospitals - Less than 6 years


#### Total Income (INR million)




#### EBITDA (INR million and margin %)



#### IPD Volumes (count)



#### ARPOB\* (INR)



\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

# H1 FY2026 performance summary

## Well capitalized balance sheet and strong EBITDA to cash flow conversion

INR million	FY2022	FY2023	FY2024	FY2025	H1 FY2026
Gross Debt	8,379	8,422	4,193	3,279	<b>5,267</b>
Cash and Cash Equivalents	5,222	13,114	11,913	11,402	<b>12,349</b>
<b>Net Debt / (Net Cash)</b>	<b>3,156</b>	<b>(4,692)</b>	<b>(7,720)</b>	<b>(8,123)</b>	<b>(7,082)</b>
Shareholder Equity	16,160	24,282	29,056	33,864	<b>37,075</b>
<b>Net Debt to Equity (x)</b>	<b>0.2x</b>	-	-	-	-
Net Cash flow from Operations	3,113	6,445	6,121	6,238	<b>3,295</b>
EBITDA <sup>1</sup>	4,898	6,771	8,737	9,562	<b>5,161</b>
<b>Cash Flow Conversion (%)</b>	<b>64%</b>	<b>95%</b>	<b>70%</b>	<b>65%</b>	<b>66%</b>
<b>Net Debt to EBITDA (x)</b>	<b>0.6x</b>	-	-	-	-

### Key Highlights

- Gross Debt increased by INR 1,988 million primarily due to loan drawdown for Noida project
- Net Cash surplus of INR 7,082 million at the end of 30<sup>th</sup> September, 2025
- Strong operating cash flow with robust EBITDA to cash flow conversion
- Capex of INR 4,252 million incurred during the period
- Well capitalized balance sheet to drive future expansion plans and growth

1. EBITDA represents EBITDA before ESOP expenses

02

## **Project Update and Capex Plan**

# Guwahati project update: Bhoomi Poojan ceremony held on 31<sup>st</sup> October, 2025

- ✓ **Land Parcel Offered:** Acquired 3.5-acre land parcel with a cost of ~Rs. 600 million
- ✓ **Strategic Location:** Newly offered land is situated along the National Highway 27
- ✓ **Enhanced Accessibility:** Prime location ensures easier access for patients and families covering entire north east region
- ✓ **Critical Advantage:** Ideal for emergency and critical care access due to improved connectivity
- ✓ Allotment, possession and lease deed executed

**Allotment Letter  
Received on  
24<sup>th</sup> October, 2025**

**Possession Taken on  
27<sup>th</sup> October, 2025**

**Bhumi Poojan  
on  
31<sup>st</sup> October, 2025**





# Medanta Mumbai to now become a ~750 bed hospital

## Super specialty hospital in Oshiwara, Mumbai




*\*The artistic image for illustration purpose only*

- ✓ The Company has bought 8,859 sq. meters of land in Oshiwara from MHADA for an amount of Rs. 125.11 crores in a public auction
- ✓ Final plot area is now 9,287.54 sqm after final measurement and company has paid Rs. 6.05 crores for additional area of 428.34 sqm
- ✓ Barricading of the site has been completed. IOA approval has been obtained, application for commencement of construction upto plinth level filed
- ✓ Soil testing is complete, and the structural consultant is currently designing the shoring, excavation, and basement construction plan based on the test results
- ✓ **Additional FSI approval received and the increased FSI has raised the allowable built-up area to 1,25,382 sq. m., enabling an increase in bed capacity from 500 to 750**
- ✓ **The facility is now expected to have a capacity of 750 beds** and will set new benchmarks in healthcare delivery, providing world-class medical services and advanced treatment options to the residents of Mumbai and surrounding regions
- ✓ **The project cost is estimated to be ~INR. 15,300 million.** The project cost includes Land cost, additional FSI purchase as well as an investment of up to INR 850 million for residential apartments for Medanta staff

# On-going expansion projects

Planned bed capacity addition; well positioned to drive near term growth


## Number of installed beds



- ❖ **Patna:** Total 37 beds added in Q2 FY2026 and 20 beds added in Q1 FY2026
- ❖ **Ranchi:** Newly built 110 bedded hospital in Ranchi, operationalized in July 2025
- ❖ **Noida with total capacity of 550 beds:** Noida commenced phase 1 of 300 beds in September, 2025 with 226 operational beds at the end of Q2 FY2026
- ❖ **South Delhi:** Announced 400 bed in partnership with DLF. Site survey complete, soil testing complete. Barricading and construction is in progress
- ❖ **Pitampura, New Delhi:** Signed O&M Agreement to jointly build and operate and manage a ~750 bed hospital. Architectural drawings submitted
- ❖ **Mumbai:** Land acquired in Mumbai in October 2024. Additional FSI approval received. Building plan currently under preparation
- ❖ **Guwahati, Assam:** Land acquisition and possession have been completed. Bhoomi Poojan ceremony held on 31st October 2025

# Capex plan next 5 years

— **Total capex of over ~INR 41,200 million planned for next 5 years**



- ❖ In H1 FY2026, **INR 4,252 million of capex incurred**
- ❖ **Maintenance capex estimated at INR ~4,500 million** to be incurred over next three years
- ❖ **Total Project capex estimated at INR ~36,700 million**, to be funded by combination of Debt funding and internal accruals

03

## **Medanta's Journey, Purpose and Model of Healthcare**

# Medanta was founded to bring a new type of healthcare to India...

## ... the human side of healthcare

Healthcare is never only about science. It is also about the **art of medicine** – the **human connection**, putting the **patient first**, **collaboration**, the personal acts of **empathy** and the **values** that guide our decision making.



At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation.

Medanta's patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy 'Har Ek Jaan Anmol', meaning 'Every Life is Invaluable'




**Dr. Naresh Trehan**  
**CMD & Chief Cardiac Surgeon, Medanta**



# Growth from a single flagship hospital in Gurgaon...

...to a network of 6 high quality hospitals across north India



- \*Carlyle Group (Anant Investments) exited completely in the IPO
- \*\* Medanta to operationalize ~110 bedded newly built hospital in Ranchi under an O&M arrangement

# From our flagship Medicity campus in Gurgaon, we have grown to ~3,435 beds across 6 cities

## Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar



### **Gurgaon**

1,440 beds; 316 ICU beds



### **LUCKNOW**

757 beds; 202 ICU beds (950 planned)



### **PATNA**

527 beds; 147 ICU beds (650 planned)



### **INDORE**

175 beds; 53 ICU beds



### **RANCHI\***

310 beds; 102 ICU beds




### **NOIDA**

226 beds; 81 ICU beds (550 planned)

# One of the largest private hospital chains in North and East India

Serving over 400 million people in the States with Medanta facilities



## Our Network

### Hospital Network

- 6 Multi-speciality hospitals
- 4 Upcoming hospitals

### Bed Capacity

3,435 Total Beds  
~2,900+ Planned Bed Addition

### Infrastructure

900+ ICU Beds  
85+ Operating Theatres

## Continuity of care

### Medanta Clinics

8 Clinics  
5 cities

### Medanta Labs

12 Labs total  
300+ Collection centre

### Pharmacy

17 Pharmacy  
4 Planned

## Our People

### Doctors

2,150+

### Nurses and paramedics

7,800+

### Full-time and retainer employees

13,250+

## Embracing a new era and redefining our purpose

### MISSION

Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge

#### Core Values



**Patient centric care:** Foster a culture where every one of us is committed to care for patients and their caregivers



**Leadership and quality:** Commit to delivering excellence in everything we do through exemplary action and behaviour




**Integrity and courage:** Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right



**Collaboration, learning and innovation:** Promote teamwork and collaboration, welcome change and creativity, encourage innovation

# The Medanta Model of Healthcare

Delivering the highest quality of medicine with care and compassion




## What it means for patients and caregivers?

- Super specialized doctors provide the highest quality of care through a team based integrated approach
- A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces
- Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment
- Doctors who take ownership and personal responsibility
- Respect-based processes for patients and their families



# Medanta is well placed to deliver sustainable growth...

...while maintaining its core values of patient centric care and clinical leadership and quality





## 04 **Annexures**

# Annexure: Profit and Loss Statement

INR million	Half Year			Quarter			
	H1 FY25	H1 FY26	Y-o-Y Growth %	Q2 FY25	Q1 FY26	Q2 FY26	Y-o-Y Growth %
<b>Revenue from operations</b>	<b>18,176</b>	<b>21,301</b>	<b>17.2%</b>	<b>9,566</b>	<b>10,308</b>	<b>10,992</b>	<b>14.9%</b>
Other income	401	402	0.1%	182	205	197	8.3%
<b>Total income</b>	<b>18,578</b>	<b>21,702</b>	<b>16.8%</b>	<b>9,748</b>	<b>10,513</b>	<b>11,189</b>	<b>14.8%</b>
Cost of materials consumed	4,368	4,946	13.2%	2,280	2,391	2,556	12.1%
Employee benefits expense	6,563	8,045	22.6%	3,366	3,852	4,193	24.6%
Other expenses	3,099	3,551	14.6%	1,637	1,717	1,834	12.1%
<b>EBITDA</b>	<b>4,548</b>	<b>5,160</b>	<b>13.5%</b>	<b>2,465</b>	<b>2,553</b>	<b>2,607</b>	<b>5.7%</b>
<b>EBITDA Margins %</b>	<b>24.5%</b>	<b>23.8%</b>	<b>(70) bps</b>	<b>25.3%</b>	<b>24.3%</b>	<b>23.3%</b>	<b>(199) bps</b>
ESOP Expenses	0	179	na	0	79	100	na
<b>EBITDA after ESOP Expenses</b>	<b>4,548</b>	<b>4,981</b>	<b>9.5%</b>	<b>2,465</b>	<b>2,474</b>	<b>2,507</b>	<b>1.7%</b>
Finance costs	340	309	(9.0)%	160	138	171	7.1%
Depreciation and amortisation expense	960	948	(1.3)%	494	451	497	0.6%
Exceptional item	0	(356)	na	0	(196)	(160)	na
<b>Profit before tax</b>	<b>3,248</b>	<b>4,080</b>	<b>25.6%</b>	<b>1,811</b>	<b>2,081</b>	<b>1,998</b>	<b>10.3%</b>
Tax expenses	877	906	3.3%	503	492	414	(17.7)%
<b>Profit after tax</b>	<b>2,371</b>	<b>3,174</b>	<b>33.9%</b>	<b>1,308</b>	<b>1,590</b>	<b>1,584</b>	<b>21.1%</b>

\*In Q2 FY26, Company reversed stamp duty payable on account of the merger of MHPL with GHL, amounting to Rs. 159.85 millions, pursuant to adjudication of its stamp duty application

\*\*In Q1 FY26, PAT is higher due to non-recurring exceptional income of Rs. 196 million arising due to reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL.

\*\*\*Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers

# Annexure: Operational Parameters

Key metrics	Year End			Quarter				
	H1 FY25	H1 FY26	Y-o-Y Growth %	Q2 FY25	Q1 FY26	Q2 FY26	Y-o-Y Growth %	Q-o-Q Growth %
Total Beds	3,008	<b>3,435</b>	14.2%	3,008	3,062	<b>3,435</b>	14.2%	12.2%
Census Beds	2,400	<b>2,573</b>	7.2%	2,446	2,487	<b>2,658</b>	8.7%	6.9%
Occupied Bed Days	2,70,636	<b>2,98,627</b>	10.3%	1,44,564	1,42,898	<b>1,55,729</b>	7.7%	9.0%
Occupancy Rate %	61.6%	<b>63.4%</b>	2.9%	64.3%	63.2%	<b>63.7%</b>	(60),bps	1.4%
ARPOB (INR)*	63,024	<b>66,055</b>	4.8%	62,141	66,584	<b>65,570</b>	5.5%	(1.5)%
ALOS (days)	3.13	<b>3.04</b>	(2.7)%	3.20	3.03	<b>3.06</b>	(4.5)%	0.9%
In-Patient Volumes	86,462	<b>98,075</b>	13.4%	45,169	47,150	<b>50,925</b>	12.7%	8.0%
Out-Patient Volumes	14,99,087	<b>17,09,565</b>	14.0%	7,75,395	8,18,815	<b>8,90,750</b>	14.9%	8.8%

- Census Beds as based on monthly average during the period
- ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
- Out-Patient volumes are sum of encounters at Out-Patient departments

## Abbreviations

- INR : Indian Rupee
- NABH : National Accreditation Board for Hospitals & Healthcare Providers
- NABL : National Accreditation Board for Testing and Calibration Laboratories
- JCI : Joint Commission International
- OPD : Out-Patient Department
- IPD : In Patient Department
- ICU : Intensive Care Unit
- Mn : Million
- ARPOB : Average Revenue Per Occupied Bed
- ALOS : Average Length of Stay
- EBITDA: EBITDA represents Profit before tax after adding back finance costs, ESOP expenses and depreciation and amortization of the relevant year/period
- EBITDA Margin : EBITDA divided by Total Income in percentage
- PAT : Profit After Tax
- NCR : National Capital Region

## Definitions

- Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds).
- Occupied beds : Total Count of patients at midnight at each day
- Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catheterization & Observation room
- ICU Beds: No of ICU Beds available in the hospital out of census beds
- Total Income : Revenue from Operations + Other Income
- ARPOB : Income from Health Care Services excluding Pharmacy and Other Income revenue divided by occupied bed days
- ALOS : Average number of days spent by admitted inpatients
- Revenue mix by Payment Type, i.e. Cash, TPA, CGHS, ECHS, PSU others.

## About Medanta

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited.

Under the “Medanta” brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,435 installed beds as on Sep 30, 2025. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 2,000+ doctors led by highly experienced department heads.

## Contact Details

**Ravi Gothwal –**  
Head of Investor Relations



+91 95996 55711



ravi.gothwal@medanta.org



### Corporate Office

#### **Medanta; The Medicity**

CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38,  
Gurgaon, Haryana 122001



**For further information, please visit our website:**

<https://www.medanta.org/>